| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2004.00.1438 |
| P698 | PubMed publication ID | 16301597 |
| P50 | author | Roy S. Herbst | Q89006575 |
| George R Blumenschein | Q94702986 | ||
| Frank V Fossella | Q94703174 | ||
| P2093 | author name string | Francisco Robert | |
| Mansoor N Saleh | |||
| Jennifer Tseng | |||
| Michael Needle | |||
| P433 | issue | 36 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cetuximab | Q420296 |
| chemotherapy | Q974135 | ||
| carboplatin | Q415588 | ||
| P304 | page(s) | 9089-9096 | |
| P577 | publication date | 2005-11-21 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer | |
| P478 | volume | 23 |
| Q38688747 | Antibodies as stratagems against cancer |
| Q21198850 | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review |
| Q46347493 | Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study |
| Q37032651 | Cetuximab in non-small cell lung cancer |
| Q55013304 | Cetuximab in non-small-cell lung cancer |
| Q35200393 | Cetuximab in non-small-cell lung cancer |
| Q46027726 | Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. |
| Q24187972 | Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer |
| Q53221921 | Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. |
| Q39745151 | Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. |
| Q36364973 | Current status of cetuximab for the treatment of patients with solid tumors. |
| Q37052752 | Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000). |
| Q58231326 | Dose-finding design driven by efficacy in onco-hematology phase I/II trials |
| Q37240726 | EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer |
| Q34216725 | EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. |
| Q24652337 | EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab |
| Q38072670 | EGFR-directed monoclonal antibodies in non-small cell lung cancer |
| Q35200322 | EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy? |
| Q36944026 | Emerging drugs for non-small-cell lung cancer |
| Q36779651 | Emerging treatments and gene expression profiling in high-risk medulloblastoma |
| Q36504349 | Epidermal growth factor receptor inhibition and non-small cell lung cancer |
| Q36482542 | Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer |
| Q39752055 | Epidermal growth factor receptor signaling in nonsmall cell lung cancer |
| Q36011603 | Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy |
| Q35738843 | Lung Cancer and Human Papilloma Viruses (HPVs): Examining the Molecular Evidence |
| Q48151414 | Mentalizing, motivation, and social mentalities: theoretical considerations and implications for psychotherapy |
| Q35001415 | Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab |
| Q34625408 | Monoclonal antibodies against EGFR in non-small cell lung cancer |
| Q36653343 | Mucosal injury from targeted anti-cancer therapy. |
| Q36974703 | New targets for non-small-cell lung cancer therapy |
| Q50050377 | Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer |
| Q39139857 | Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer |
| Q35667782 | Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC) |
| Q34488787 | Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342 |
| Q35023433 | Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324 |
| Q33378256 | Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study |
| Q79452041 | Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues |
| Q35170255 | Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. |
| Q37771250 | Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. |
| Q37679981 | Role of epidermal growth factor receptor in lung cancer and targeted therapies |
| Q47841542 | Safety and efficacy of cetuximab combined with chemotherapy in Chinese patients with advanced non-small cell lung cancer |
| Q44521642 | Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases |
| Q37760357 | Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? |
| Q37175922 | Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays. |
| Q37645161 | Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer |
| Q35184402 | Targeted dendrimer chemotherapy in an animal model for head and neck squamous cell carcinoma |
| Q35628597 | Targeted therapies for non-small cell lung cancer: an evolving landscape |
| Q37765472 | Targeted therapy in non-small-cell lung cancer--is it becoming a reality? |
| Q37768460 | Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer |
| Q36858198 | Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? |
| Q33242719 | Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). |
| Q34088424 | Understanding resistance to EGFR inhibitors-impact on future treatment strategies |
| Q43745972 | Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial |
Search more.